Codexis. has filed a patent for methods of expressing recombinant neprosin polypeptide, along with host cells and expression vectors. The patent also covers using the expressed neprosin polypeptide for therapeutic purposes. Claim 1 specifies the amino acid sequence requirements for the recombinant neprosin polypeptide. GlobalData’s report on Codexis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Codexis Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Codexis, Bioethanol production GMOs was a key innovation area identified from patents. Codexis's grant share as of January 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Recombinant neprosin polypeptide with high sequence identity

Source: United States Patent and Trademark Office (USPTO). Credit: Codexis Inc

The patent application (Publication Number: US20240026331A1) discloses a recombinant neprosin polypeptide with specific amino acid sequences and substitutions. The polypeptide must have a sequence identity of at least 80% to a reference sequence corresponding to specific positions in the pre-pro-polypeptide, pro-polypeptide, mature polypeptide, or polypeptide of SEQ ID NO: 1. The amino acid sequence should include substitutions at positions 68, 145, 152, or 253 with amino acids other than asparagine. Additionally, the signal sequence of the pre-pro-polypeptide can be replaced with a signal sequence functional in mammalian, insect, or fungal cells.

Furthermore, the patent application covers methods of expressing the recombinant neprosin polypeptide, preparing mature neprosin polypeptide, and treating diseases associated with gluten intolerance using the disclosed polypeptides. The methods involve culturing host cells under suitable conditions for expression, treating pre-pro-polypeptides or pro-polypeptides to form mature neprosin polypeptides, and administering effective amounts of the polypeptides to subjects in need. The application also includes pharmaceutical compositions containing the pro-polypeptide or mature neprosin polypeptide for therapeutic use in gluten intolerance-related conditions.

To know more about GlobalData’s detailed insights on Codexis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies